Amgen Off-label Settlement Includes Exec Oversight Of Individual Product Compliance

Amgen pled guilty to off-label promotion of Aranesp, and settled civil claims of kickbacks, false price reporting and off-label promotion of other drugs; Sanofi settles claims it provided kickbacks in the form of free Hyalgan samples.